Wiley Blackwell

SHERPA: Unknown

People

  1. Motzer
    Motzer
  2. Kemeny
    Kemeny
  3. Horwitz
    Horwitz
  4. Marghoob
    Marghoob
  5. Kelsen
    Kelsen
  6. Scher
    Scher
  7. Hudis
    Hudis
  8. O'Reilly
    O'Reilly
  9. Tuttle
    Tuttle
  10. Bajorin
    Bajorin

Groups

  1. Department of Medicine (1537)
  2. Solid Tumor Oncology Division (892)
  3. Survivorship Research (499)
  4. Hematologic Malignancies, Division of (432)
  5. Division of Subspecialty Medicine (380)
  6. Center for Hematologic Malignancies (343)
  7. Population Sciences Research Program (289)
  8. Genitourinary Oncology Service (269)
  9. GSK Faculty (263)
  10. Surgery (257)
Search Within
  1. "Department of Medicine"
Formats
  1. Journal Article (982)
  2. Meeting Abstract (382)
  3. Review (52)
  4. Book Section (37)
  5. Research Letter (28)
  6. Editorial (26)
  7. Conference Paper (13)
  8. Guidelines (8)
  9. Correspondence (6)
  10. Miscellaneous (2)
  11. Book Whole (1)
Groups
  1. Department of Medicine (1537)
  2. Solid Tumor Oncology Division (892)
  3. Survivorship Research (499)
  4. Hematologic Malignancies, Division of (432)
  5. Division of Subspecialty Medicine (380)
  6. Center for Hematologic Malignancies (343)

More Groups

People
  1. Robert Motzer (87)
  2. Nancy Kemeny (59)
  3. Steven Horwitz (55)
  4. Ashfaq Marghoob (53)
  5. David Kelsen (49)
  6. Howard Scher (46)

More People

Years
  1. 2025 (48)
  2. 2024 (60)
  3. 2023 (133)
  4. 2022 (54)
  5. 2021 (106)
  6. 2020 (81)

More Years

Publications
  1. Cancer (541)
  2. Hematological Oncology (167)
  3. BJU International (75)
  4. Journal of Surgical Oncology (61)
  5. Asia-Pacific Journal of Clinical Oncology (58)
  6. Cancer Medicine (58)

More Publications

Results (1537)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Enhancing T‐cell responses to GCB‐like lymphomas with immune‐checkpoint‐blockade‐based therapies
    Meeting Abstract

    Serganova, I.; Bucktrout, R.; Isshiki, Y.; Sarapulov, A.; Santella, A.; Rodriguez, M.; Chakraborty, S.; Brunschvig, S.; Qualls, D.; Vardhana, S.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Lisocabtagene maraleucel (LISO‐CEL) versus standard of care (SOC) as second‐line therapy in large B‐cell lymphoma (TRANSFORM study): Subgroup analyses by prior therapy response
    Meeting Abstract

    Nastoupil, L. J.; Kamdar, M.; Chavez, J. C.; Ghesquieres, H.; Ghosh, M.; Holmes, H.; López‐Guillermo, A.; Martínez‐López, J.; Novak, U.; Ribrag, V.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • AFM13 in patients with CD30 positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL): Results from the phase 2 redirect study
    Meeting Abstract

    Kim, W. S.; Shortt, J.; Zinzani, P. L.; Mikhaylova, N.; Marin‐Niebla, A.; Radeski, D.; Ribrag, V.; Domenech, E. D.; Sawas, A.; Alexis, K.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • High complete metabolic response rates with epcoritamab + R‐CHOP in previously untreated (1L) high‐risk DLBCL, including double‐hit/triple‐hit: EPCORE NHL‐2 update
    Meeting Abstract

    Falchi, L.; Clausen, M. R.; Offner, F.; de Vos, S.; Brody, J.; Linton, K. M.; Snauwaert, S.; Cordoba, R.; Wu, J.; Bykhovski, I.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • BRCA1/2 mutations impact on the development of breast implant‐associated lymphoma (BIA‐ALCL) in women with breast cancer reconstructed with textured breast implants
    Meeting Abstract

    Ghione, P.; Arcila, M.; Joseph, V.; Dogan, A.; Cordeiro, P.; Salles, G.; de Jong, D.; Horwitz, S.; Mandelker, D.; van Leeuwen, F.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Impact of response to systemic bridging therapy on clinical outcomes and cytokine profile in patients receiving CAR T‐cell therapy for aggressive B‐cell lymphoma
    Meeting Abstract

    Wills, B.; Shouval, R.; Flynn, J.; Devlin, S. M.; Shah, G. L.; Scordo, M.; Dahi, P. B.; Lin, R. J.; Imber, B.; Parascondola, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Circulating tumor DNA (CTDNA) status and clinical outcomes in patients (PTS) with previously untreated diffuse large B‐cell lymphoma (DLBCL) in the POLARIX study
    Meeting Abstract

    Herrera, A. F.; Tracy, S.; Sehn, L. H.; Jardin, F.; Lenz, G.; Trněný, M.; Salles, G.; Flowers, C. R.; Tilly, H.; Sharman, J. P.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Chromatin accessibility profiling to increase diagnostic accuracy and refine cell‐of‐origin classification of mature T‐cell lymphomas
    Meeting Abstract

    Julia, E.; Mareschal, S.; Chebel, A.; Camille, G.; Missaglia, E.; Rattina, V.; Lours, C.; Testard, Q.; Tschantz, M.; Sebai, S.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save